Cue Biopharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 3/6

Cue Biopharma şirketinin toplam hissedar öz sermayesi $25.4M ve toplam borcu $5.3M olup, bu da borç-öz sermaye oranını 20.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $44.8M ve $19.4M dir.

Anahtar bilgiler

20.9%

Borç/özkaynak oranı

US$5.29m

Borç

Faiz karşılama oranın/a
NakitUS$32.42m
EşitlikUS$25.37m
Toplam yükümlülüklerUS$19.44m
Toplam varlıklarUS$44.81m

Son finansal sağlık güncellemeleri

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11
Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Recent updates

Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Apr 16
Here's Why Cue Biopharma (NASDAQ:CUE) Can Manage Its Debt Despite Losing Money

Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Dec 30
Does Cue Biopharma (NASDAQ:CUE) Have A Healthy Balance Sheet?

Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Aug 11
Is Cue Biopharma (NASDAQ:CUE) Using Too Much Debt?

Cue Biopharma shares rise ~10% on FDA fast track nod for head and neck cancer drug

Oct 04

Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

Sep 23
Despite Lacking Profits Cue Biopharma (NASDAQ:CUE) Seems To Be On Top Of Its Debt

News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Aug 26
News Flash: 4 Analysts Think Cue Biopharma, Inc. (NASDAQ:CUE) Earnings Are Under Threat

Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Aug 10
Analysts Just Shipped A Huge Upgrade To Their Cue Biopharma, Inc. (NASDAQ:CUE) Estimates

Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

May 18
Analysts Have Just Cut Their Cue Biopharma, Inc. (NASDAQ:CUE) Revenue Estimates By 23%

Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

May 12
Cue Biopharma (NASDAQ:CUE) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Cue Biopharma: A First Assessment

May 11

Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Mar 19
Earnings Beat: Cue Biopharma, Inc. (NASDAQ:CUE) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

Cue Biopharma: Too Long To Arrive At Topline Trial Data

Feb 23

We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Nov 04
We Think Cue Biopharma (NASDAQ:CUE) Can Afford To Drive Business Growth

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: CUE 'nin kısa vadeli varlıkları ( $37.3M ) kısa vadeli yükümlülüklerini ( $16.8M ) aşıyor.

Uzun Vadeli Yükümlülükler: CUE şirketinin kısa vadeli varlıkları ( $37.3M ) uzun vadeli yükümlülüklerini ( $2.7M ) aşmaktadır.


Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: CUE şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: CUE şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 20.9% seviyesine yükseldi.


Bilanço


Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: CUE şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: CUE un, serbest nakit akışı her yıl % 7.1 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır


Sağlıklı şirketleri keşfedin